. Development and Validation of Multiplex Assays for Lupus Nephritis Activity Biomarkers. Kidney International Reports. 2025; 10:2255-2264.
. POS0295 RELATIONSHIP AMONG A PEDIATRIC-SPECIFIC ULTRASOUND SCORING SYSTEM FOR THE EVALUATION OF ARTHRITIS AND BIOLOGIC MARKERS OF INFLAMMATION. Annals of the Rheumatic Diseases. 2025; 84:556.
. Clinical, Immunologic, and Genetic Characteristics in Patients With Syndrome of Undifferentiated Recurrent Fevers. Arthritis and Rheumatology. 2025; 77:596-605.
. Candidate Tear-Based Uveitis Biomarkers in Children with JIA Based on Arthritis Activity and Topical Corticosteroid Use. Ocular Immunology and Inflammation (Informa). 2025; 33:603-612.
. Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction. Arthritis Care and Research. 2025; 77:513-521.
. Allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease: outcomes from an international, retrospective cohort study. The Lancet. Rheumatology. 2025; 7:e243-e251.
. Achieving Medication-Free Remission in Patients With Juvenile Dermatomyositis. ACR Open Rheumatology. 2025; 7:e11751.
. Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project. Rheumatology. 2025; 64:32-44.
. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Research and Therapy. 2024; 26:125.
. Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76:1723-1732.
. EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. Annals of the Rheumatic Diseases. 2024; 83:1614-1627.
. Enrichment of Rare Variants of Hemophagocytic Lymphohistiocytosis Genes in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology. 2024; 76:1566-1572.
. Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry. Rheumatology. 2024; 63:SI195-SI206.
. Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease. Arthritis Care and Research. 2024; 76:328-339.
. Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature. Arthritis and Rheumatology. 2024; 76:455-468.
. Diagnostic Accuracy Study of the Pediatric-Specific Ultrasound Scoring System for the Knee Joint in Children With Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76:251-258.
. Proceedings from the 4th NextGen Therapies for SJIA and MAS virtual symposium held February 13-14, 2022. Pediatric Rheumatology Online Journal. 2024; 21:91.
. The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA. Pediatric Rheumatology Online Journal. 2024; 21:87.
. Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Pediatric Rheumatology Online Journal. 2024; 21:86.
. The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study. Pediatric Rheumatology Online Journal. 2024; 21:150.
. Genetics of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. Advances in Experimental Medicine and Biology. 2024; 1448:121-126.
. Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants. Arthritis and Rheumatology. 2024; 76:119-129.
. Population-level single-cell genomics reveals conserved gene programs in systemic juvenile idiopathic arthritis. The Journal of Clinical Investigation. 2023; 133:e166741.
. Diagnosis and Management of the Systemic Juvenile Idiopathic Arthritis Patient with Emerging Lung Disease. Pediatric Drugs. 2023; 25:649-658.
. The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). Arthritis and Rheumatology. 2023; 75:1714-1732.
. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Annals of the Rheumatic Diseases. 2023; 82:1271-1285.
. OP0166 LONG-TERM FOLLOW-UP OF PATIENTS ADMINISTERED EMAPALUMAB, AN ANTI–INTERFERON-Γ MONOCLONAL ANTIBODY, TO TREAT MACROPHAGE ACTIVATION SYNDROME (MAS) SECONDARY TO SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). Annals of the Rheumatic Diseases. 2023; 82:110-111.
. Efficacy and safety of emapalumab in macrophage activation syndrome. Annals of the Rheumatic Diseases. 2023; 82:857-865.
. Lung Ultrasound in Children With Systemic Juvenile Idiopathic Arthritis-Associated Interstitial Lung Disease. Arthritis Care and Research. 2023; 75:983-988.
. Implementing Research Shared (Core) Facility Billing Systems. Journal of biomolecular techniques : JBT. 2022; 33:3fc1f5fe.1a877626.
. Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis. American Journal of Ophthalmology. 2022; 244:183-195.
. Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis. Arthritis and Rheumatology. 2022; 74:1271-1283.
. Establishing a biosafety plan for a flow cytometry shared resource laboratory. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2022; 101:380-386.
. International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. Arthritis and Rheumatology. 2022; 74:263-273.
. S100 proteins, cytokines, and chemokines as tear biomarkers in children with juvenile idiopathic arthritis-associated uveitis. Ocular Immunology and Inflammation (Informa). 2021; 29:1616-1620.
. Targeting interferon-γ in hyperinflammation: opportunities and challenges. Nature reviews. Rheumatology. 2021; 17:678-691.
. IFN-γ is essential for alveolar macrophage-driven pulmonary inflammation in macrophage activation syndrome. JCI insight. 2021; 6:e147593.
. Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study. The Lancet. Rheumatology. 2021; 3:e563-e573.
. Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study. The Lancet. Rheumatology. 2021; 3:e574-e584.
. Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology. 2021; 73:1334-1340.
. Repression of CTSG, ELANE and PRTN3-mediated histone H3 proteolytic cleavage promotes monocyte-to-macrophage differentiation. Nature Immunology. 2021; 22:711-722.
. Platelet Glycoprotein Ib α-Chain as a Putative Therapeutic Target for Juvenile Idiopathic Arthritis: A Mendelian Randomization Study. Arthritis and Rheumatology. 2021; 73:693-701.
. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Annals of the Rheumatic Diseases. 2021; 80:406-408.
. Remote Training of SRL Users and Staff in a Global Pandemic. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2021; 99:42-50.
. Biosafety during a pandemic: shared resource laboratories rise to the challenge. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2021; 99:68-80.